[HTML][HTML] Targeting T cell co-receptors for cancer therapy
MK Callahan, MA Postow, JD Wolchok - Immunity, 2016 - cell.com
MK Callahan, MA Postow, JD Wolchok
Immunity, 2016•cell.comCheckpoint-blocking antibodies can generate potent anti-tumor responses by encouraging
the immune system to seek and destroy cancer cells. At this time, the United States Food
and Drug Administration has approved three checkpoint-blocking antibodies in three
disease indications, and additional approvals are expected to broaden the clinical scope of
immunotherapy. Herein, we review the clinical development of CTLA-4-, PD-1-, and PD-L1-
blocking antibodies across tumor types and briefly discuss areas of active investigation of …
the immune system to seek and destroy cancer cells. At this time, the United States Food
and Drug Administration has approved three checkpoint-blocking antibodies in three
disease indications, and additional approvals are expected to broaden the clinical scope of
immunotherapy. Herein, we review the clinical development of CTLA-4-, PD-1-, and PD-L1-
blocking antibodies across tumor types and briefly discuss areas of active investigation of …
Checkpoint-blocking antibodies can generate potent anti-tumor responses by encouraging the immune system to seek and destroy cancer cells. At this time, the United States Food and Drug Administration has approved three checkpoint-blocking antibodies in three disease indications, and additional approvals are expected to broaden the clinical scope of immunotherapy. Herein, we review the clinical development of CTLA-4-, PD-1-, and PD-L1-blocking antibodies across tumor types and briefly discuss areas of active investigation of potential biomarkers.
cell.com
